Search Results

working with distinct chemical scaffolds like thiazolidines and xanthinediones, Ben is helping define how structurally team aims to understand how and where these compounds interact with the receptor, paving the way for structure-based Structural Biology Roadblocks: The Cryo-EM Challenge One bottleneck in Ben’s work is visualizing binding Still, by collaborating with structural biology teams and combining cryo-EM with NMR , his lab is narrowing Clements' work is primarily focused on translational developments of small molecule therapeutics, and

neuronal circuits — insights that inform next-generation functional assay development and translational therapeutic collaborative chemistry enabled in designing receptor-targeted fluorescent ligands The moment when structural

Each session explores mechanistic models, translational challenges, and real-world therapeutic implications These webinars are ideal for: • GPCR pharmacologists • Medicinal chemists working on receptor targets • Structural Calcium and signaling assays • Drug–receptor kinetics • Translational pharmacology strategies • GPCR structure–function

of this work centered on elucidating novel mechanisms by which β-adrenergic receptors impact cardiac structure GPCRs in the regulation of physiologic/pathologic function in the heart in an effort to uncover novel therapeutic

of Canada (2014), the Julie Axelrod award from the American Society of Pharmacology and Exerimental Therapeutics able to work with him and his team and use the tools developed in his lab to better understand GPCR structure

CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Session V Structural mechanisms of AGPCR signaling and function Structural Determinants Of GAIN Domain Autoproteolysis And Cleavage Resistance Of Adhesion G Protein-Coupled Receptors Fabian Pohl Structural studies of the CELSR1 We de-termined the crystal structure of the human ADGRB2/BAI2 hormone receptor (HormR) and GAIN domains unique structural features that are important for autoproteolytic cleavage, beyond the canonical HXS

technology platform deciphering cell signaling pathways combined with AI-based approaches to elucidate structure the company's ability to predict the residence time of a ligand and its potential correlation with a therapeutic Therapeutic Effect and Receptor Interactions Aurelien Rizk and Yamina had a detailed discussion about the importance of gaining more information about the therapeutic effect in patients or animals and the They also shared their preference for small molecule therapies over protein therapeutics.

He is pioneering the investigation of animal toxins acting on GPCRs, the largest therapeutic target class His strongest expertise lies in therapeutic target identification and all the steps from venom manipulations pharmacological properties of these new ligands are deemed exceptional, a lead optimization is realized and its therapeutic

Pina Cardarelli, CSO for GPCR Therapeutics Inc., based in South Korea, has recently been named President of GPCR Therapeutics, USA, a newly incorporated Biotechnology company in the Bay Area. The company’s mission is to discover and develop highly effective cancer therapeutics by targeting heteromers She was an integral contributor to two therapeutics that are FDA approved, Yervoy and Opdivo. patents including anti-PD-1 patents, 22 EP patents, and greater than 100 global patents centered around therapeutic

I then started my career at Evotec before moving to Domain Therapeutics (called Faust pharmaceutical chemistry. 6 years ago I decided to take on a new challenge by taking the position of CSO at Confo Therapeutics Christel Menet on the web Hyphen Projects GPCRS Drug Discovery Confo Therapeutics LinkedIn Dr.

collaborative neuroscience R&D program with Servier (France) and is the co-founder and CEO of Phrenix Therapeutics , a biotech spin-out from the Neuromedicines Discovery Centre that is developing next-generation therapeutics Prior to these roles this he was Head of Pharmacology at Heptares Therapeutics Ltd., a UK-based biotechnology These successes enabled the US$400M sale of Heptares Therapeutics Ltd. to the Sosei Group Corporation

With a deep focus on structure-based drug design, Jens discusses how his lab bridges simulation and experiment—and From virtual screening of billions of molecules to leveraging AlphaFold for structure prediction, Jens You’ll Learn Why Jens Carlsson believes modeling should predict , not just explain How his team uses structure-based collaborations between modelers and experimentalists are more vital than ever How AlphaFold is shaking up structural a research career Who Should Listen GPCR scientists and pharmacologists Computational chemists and structural

into industry, and his role leading and shaping multidisciplinary teams for screening and innovative therapeutics How advanced assay design is essential for translating cell-based GPCR signals to therapeutic outcomes Martin Marro leads the Cell Pharmacology group in the Diabetes, Obesity and Complications Therapeutic Marro’s career advanced through roles at Novartis and Tectonic Therapeutic, contributing to projects across key therapeutic areas—spanning metabolic, cardiovascular, and gastrointestinal diseases.

He earned his PhD in Physics at the same university, focusing on in silico structural vaccinology and Now in a tenure-track position, his research spans the development of computational methods such as structure-based Scholar ResearchGate Bysky App : @ riccardocapelli.bsky.social Twitter X : @ ric_capelli Computational Structural

signaling mechanisms employed by these atypical 7-transmembrane receptors, combining biochemical and structural begun studying GPCR signaling pathways that operate within the primary cilium, a tiny antenna-shaped structure Prior to that, Ben received his Ph.D. from UCSF in 2008, where he worked with David Julius on the structure

Ray Stevens in 2013 solving several GPCR crystal structures, including that of the first serotonin receptor Bryan Roth where I established GPCR structural biology and learned the ins and outs of molecular pharmacology started my own lab at the Icahn School of Medicine at Mount Sinai in NYC, where I have been working on structure-function

He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics of GPCRs in disease states to help test the feasibility of using protein-targeted degradation as a therapeutic Maddi is currently a second year Ph.D. student in the Molecular Pharmacology and Therapeutics (MPaT)

With hundreds of subtypes and very few known ligands, the structure–function relationships remain largely .” – Alessandro Nicoli He explained how AlphaFold’s predictions, surprisingly close to experimental structures More structures, better tools, and deeper insights into the elegant, complex world of GPCRs. By bridging structural prediction, molecular dynamics, and ligand discovery, his work not only deciphers Alessandro PhD work aims to fill these gaps by leveraging computational structure-based tools and develop

He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics

overcome these obstacles by producing high-quality antibodies that more accurately mimic natural protein structures This approach contrasts with other antigen forms like peptides or DNA, which face limitations in structural

Martin Audet Structural biologist, pharmacologist, and a professor of pharmacology at Université de Sherbrooke the AudetLab located at the Institute of Pharmacology of Sherbrooke and is an emerging leader in the structural

Communications, which she joined in April 2020, following three years on the editorial teams of Nature Structural Katarzyna handles submissions in structural biology, biophysics and biochemistry, with a particular focus

He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics

company supporting pharmaceutical, life science, and academic scientists in the development of new therapeutics analysis of drug action and is known for applying binding kinetics to the development of effective therapeutics

He is the scientific founder of two biotech companies, ModMab Therapeutics , and AntlerA Therapeutics

I aim to discover new therapeutic approaches, and druggable molecules or refine canonical drug targets while performing various cell-based experiments to understand the binding, activation, and signaling of therapeutically

Current affiliation: Department of Structural Biology, Genentech, South San Francisco, CA, USA" About Kordon "I am a postdoctoral scholar in the Araç Lab at The University of Chicago, studying the structure Utilizing synthetic antibody fragments, I aim to understand better the structural basis of the aGPCRs University of Copenhagen, Copenhagen, Denmark. (2) Department of Psychiatry and Molecular Pharmacology and Therapeutics Columbia University Vagelos College of Physicians and Surgeons, New York, USA; Division of Molecular Therapeutics

Brain’s work there primarily focused on structure prediction of GPCRs from sparse experimental data. of California in San Francisco to continue his training as a postdoctoral researcher where he used structural

GPCR signal transduction and neuroscience, and she has expanded it in the areas of drug discovery and structural Her research focuses on the structure and function of GTP binding proteins and the molecular mechanisms studying G protein coupled signal transduction for many years and has made key discoveries in G protein structure

particular, drives tumor growth via effects on GBM stem cell self-renewal and metabolism, but also has a therapeutically has been particularly interested in the role adhesion GPCRs play in glioblastoma biology and their therapeutic Javitch1,2 1Departments of Psychiatry and Molecular Pharmacology and Therapeutics, Columbia University , New York, NY 10032; 2Division of Molecular Therapeutics, New York State Psychiatric Institute, New